CRDF News and Press, Cardiff Oncology Inc. From 08/08/23

2023-08-08 12:45:03 ET More on Pfizer Pfizer Inc. ( PFE ) Q2 2023 Earnings Call Transcript How Pfizer Stands In My Investment Plans For Our Dividend Growth Portfolio Pfizer: Significant Plunge, Offering Exceptional Buying Opportunity Pfizer: A 4.5% Divide...

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship PR Newswire - Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA - ...

2023-06-07 10:01:47 ET Gainers: Avrobio ( AVRO ) +10% . Cardiff Oncology ( CRDF ) +8% . IceCure Medical ( ICCM ) +7% . Humacyte ( HUMA ) +6% . TScan Therapeutics ( TCRX ) +4% . Losers: Vaxart ( VXRT ) -27% . Carism...

Cardiff Oncology to Present at the Jefferies Healthcare Conference PR Newswire SAN DIEGO , June 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug t...

2023-05-29 00:33:32 ET Summary Cardiff is a small-cap biotech hinging their success on one drug. Most of their focus is on one disease area as well which recently entered phase 2 study. The cash runway does not currently allow for the completion of the phase 2 study, let alone...

2023-05-12 10:10:00 ET Vancouver, Kelowna, Delta, BC - May 12, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in biotech, mining, retail and entertainment. Today's stocks have been...

2023-05-04 17:41:13 ET Cardiff Oncology press release ( NASDAQ: CRDF ): Q1 GAAP EPS of -$0.25 misses by $0.02 . Revenue of $0.08M (+14.3% Y/Y) beats by $0.02M . As of March 31, 2023, Cardiff Oncology had approximately $97.0 million in cash, cas...

Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update PR Newswire First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Sci...

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer PR Newswire SAN DIEGO , March 28, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage bi...

Cardiff Oncology Formally Introduces Scientific Advisory Board PR Newswire - SAB includes recognized leaders with expertise in oncology drug development, pharmaceutical industry dynamics and translational research – - SAB will continue to provide insight and gui...